Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-12-02
1998-10-06
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530327, 530328, 514 15, A61K 3800, C07K 708
Patent
active
058176284
ABSTRACT:
This invention provides a method of suppressing the cytotoxic activity of mammalian Natural Killer (NK) cells.
The method of this invention comprises administering to an individual in need of treatment a polypeptide comprising the amino acid sequence corresponding to dynorphin A or a dynorphin A analog, including amidated analogs, in an amount sufficient to suppress the cytotoxic activity of NK cells. This invention is particularly useful for those individuals undergoing gene therapy who are to be infected with a viral or viroid vector containing a therapeutic gene. This invention is also useful to aid recipients of transplanted tissue and for individuals suffering from autoimmune diseases.
REFERENCES:
patent: 4361553 (1982-11-01), Loh et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4481191 (1984-11-01), Wei et al.
patent: 4537878 (1985-08-01), Plotnikoff et al.
patent: 4684624 (1987-08-01), Hosobuchi et al.
patent: 4707468 (1987-11-01), Yoshino et al.
patent: 4757049 (1988-07-01), Plotnikoff et al.
patent: 4801614 (1989-01-01), Plotnikoff et al.
patent: 5017689 (1991-05-01), Hruby et al.
Oleson, et al.; Brain, Behavior, and Immunity 2:171-186 (1988).
Cseuz, et al.; British Journal of Rheumatology 29:258-362 (1990).
R.M. Silver; Clinical and Experimental Rheumatology 8:481-486 (1990).
Nakamura, et al.; Diabetes, 39:836-843 (1990).
Rose; Clinical Immunology and Immunopathology 53;S7-S16 (1989).
Grunebaum, et al.; Immunol. Res. 8:292-304 (1989).
W.F. Hickey, et al.; J. Exp. Med. 176:811-817 (Sep. 1990).
S.J. Richards; Leukemia and Lymphoma, 7:377-399 (1992).
M.S. Shachner, et al.; Journal of Surgical Research 52:601-604 (1992).
G.F. Solomon; Int. J. Sports Med. 12:S50-S52 (1991).
Prete, et al.; "The In Vitro Effects of Endogenous Opiates on Natural Killer Cells, Antigen-Specific Cytolytic T-Cells, and T-Cell Subsets"; Experimental Neurology, May 1986, vol. 92, No. 2, pp. 349-359.
Prete, et al.; "The Effect of Neuropeptides on Mitogenic Responses, and NK Activity in Systemic Lipus Erythematosus (SLE)". Federation of American Societies for Experimental Biology, 71st Annual Meeting; 29 Mar. 1987, Washington, D.C., Abstract No. 1327, p. 544.
Taylor, et al.; "Peptide Models of Dynorphin A (1-17) Incorporating Minimally Homologous Substitutes for the Potential Amphiphilic Beta Strand in Residues 7-15"; Biochemistry; vol. 29, No. 22, 5 Jun. 1990, pp. 5364-5373.
Hata, Kensaku et al.; "Natural Killer Activity of Human Liver--Derived Lymphocytes in Various Liver Diseases"; Hepatology, Sep. 1991, vol. 14, No. 3, pp. 495-503.
Mulligan, Richard C.; "Gene Transfer And Gene Therapy--Principles, Prospects, and Perspective"; Etiology of Human Disease at the DNA Level, 1991, pp. 143-189.
Oshshorn, Miriam et al.; "In Vitro Studies of the Effect of Methadon on Natural Killer Cell Activity"; Israel Journal of Medical Sciences, Aug. 1990, vol. 26, No. 8, pp. 421-425.
Rosenberg, Steven A., M.D., Ph.D. et al.; "Gene Transfer Into Humans--Immunotherapy Of Patients With Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified By Retroviral Gene Transduction"; The New England Journal of Medicine, Aug. 30, 1990, vol. 323, No. 9, pp. 571-578.
Mary Jeanne Kreek, "Immune Function in Heroin Addicts and Former Heroin Addicts In Treatment: Pre- and Post-AIDS Epidemic", NIDA Research Monograph Series, 1990, vol. 96, pp. 192-219.
Novick, David M. et al.; "Natural Killer Cell Activity and Lymphocyte Subsets in Parenteral Heroin Abusers and Long-term Methadone Maintenance Patients"; The Journal of Pharmacology and Experimental Therapeutics, Aug. 1989, vol. 250, No. 2, pp. 606-610.
Smith, Andrew P. and Nancy M. Lee,; "Pharmacology Of Dynorphin"; Annual Review of Pharmacology and Toxicology, 1988, vol. 28, pp. 123-140.
Sibinga, Nicholas E.S. and Avram Goldstein; "Opioid Peptides And Opioid Receptors In Cells Of The Immune System"; Annual Review of Immunology, 1988, vol. 6, pp. 219-249.
Mandler, Raul N. et al.; ".beta.-Endorphin Augments The Cytolytic Activity and Interferon Production of Natural Killer Cells"; 1986, The Journal of Immunology, vol. 136, No. 3, pp. 934-939.
Joseph Wybran; "Enkephalins and Endorphins As Modifiers of the Immune System: Present and Future"; Federation Proceedings, Jan. 1985, vol. 44, No. 1, pp. 92-94.
Kay, Neil et al.; "Endorphins Stimulate Normal Human Peripheral Blood Lymphocyte Natural Killer Activity"; Life Sciences, 1984 vol. 35, pp. 53-59.
Faith, Robert E. et al.; "Neuroimmunomodulation with Enkephalins: Enhancement of Human Natural Killer (NK) Cell Activity in Vitro"; Clinical Immunology and Immunopathology, 1984, vol. 31, pp. 412-418.
Jen, M.F. et al.; "Dynorphin-(1-13): The Effect Of In Vivo Treatment On Opiate Bindings In Vitro"; European Journal of Pharmacology, 1983, vol. 91, pp. 95-99.
Mathews, Paul M. et al.; "Enhancement of Natural Cytotoxicity By .beta.-Endorphin", The Journal of Immunology, Apr. 1983, vol. 130, No. 4, pp. 1658-1662.
Chavkin, Charles et al.; "Dynorphin Is a Specific Endogenous Ligand of the .kappa. Opioid Receptor"; Science; Jan. 22, 1982, vol. 215, No. 4531, pp. 413-415.
Laidlow, Stewart A. and Kivie Moldave; "The Effects of .beta.-Endorphin and Enkephalins on Protein Biosynthesis in a Eurkaryotic Cell-Free System", The Journal of Biological Chemistry, Dec. 1980, vol. 255, No. 24, pp. 11908-11913.
Goldstein, Avram et al.; "Dyhorphin-(1-13), An Extraordinarily Potent Opioid Peptide," Proceedings of the National Academy of Sciences, Dec. 1979, vol. 76, No. 12, pp. 6666-6670.
Mary Jeanne Kreek, "Medical Complications In Methadone Patients", Annals of The New York Academy of Sciences, 1978, vol. 311, pp. 110-134.
Marshall S. G.
The Rockefeller University
Tsang Cecilia J.
LandOfFree
Dynorphin a suppression of natural killer cell activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dynorphin a suppression of natural killer cell activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dynorphin a suppression of natural killer cell activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77059